Fish Oil Benefits: The Real One Needs a Prescription

There is a genuine, well-evidenced benefit to omega-3. The American Heart Association wrote a science advisory recommending it.

It requires four grams a day, a prescription, and a blood test result most people buying fish oil have never had. [2]

The capsule in your cupboard is a different proposition, and it has been tested about as thoroughly as anything in nutrition.

What 86 trials and 162,796 people found

In 2020 Cochrane — the organisation that exists to pool trials without a commercial stake in the answer — updated its review of omega-3 and cardiovascular disease. Eighty-six randomised trials. Doses from half a gram to more than five grams a day. Follow-up from one year to more than seven. [1]

86 trials · 162,796 people · with the certainty grade attached
Outcome Result Certainty
Dying of anything no effect High
Cardiovascular events no effect High
Stroke no effect Moderate
Cardiovascular death 8% lower Moderate
Coronary heart disease events 9% lower Low
Eating fish, rather than capsules little evidence
Cochrane 2020. Certainty is the reviewers’ own GRADE rating — how much confidence the evidence itself deserves, separate from the result.

Look at the right-hand column, because it is the part that almost never gets quoted. Certainty is a separate judgement from the result: it is how much confidence the evidence itself deserves, given how the trials were run and how consistent they were.

On dying of anything, and on cardiovascular events, the answer is no effect — at high certainty. That is the strongest grade Cochrane issues. It does not mean the question is closed forever, but it does mean more trials of the same kind are unlikely to change the answer.

Two smaller signals survived. Cardiovascular death came out about 8% lower at moderate certainty. Coronary heart disease events about 9% lower — but at low certainty, with a number needed to treat of 167. That last figure means: if 167 people take fish oil, one of them avoids an event who otherwise would not have. The other 166 get nothing.

And one line from the review deserves its own paragraph, because it undercuts the advice everybody gives: “There is little evidence of effects of eating fish.” [1]

The biggest trial of the capsule people actually buy

VITAL is the one designed to answer the consumer question directly: 25,871 healthy older adults, one gram a day of marine omega-3, versus placebo, for a median of 5.3 years. [3]

Major cardiovascular events: 386 on omega-3, 419 on placebo. Hazard ratio 0.92, and a p-value of 0.24 — comfortably inside the range you get from chance. Cancer: no difference either.

There is one result in VITAL worth being careful with. Total heart attacks came out significantly lower on omega-3, a hazard ratio of 0.72. [3] That is a real number and an interesting one.

It is also a secondary endpoint inside a trial whose primary endpoint was null. Trials measure many things; some of them come out significant by chance, which is precisely why one outcome is nominated in advance as the one that counts. When the headline result is negative and a sub-result is positive, the honest description is “worth following up”, not “fish oil prevents heart attacks”.

So what is the real benefit?

Triglycerides. A type of fat in your blood, separate from cholesterol, and high levels are their own cardiovascular risk factor.

The American Heart Association’s 2019 advisory is unambiguous: at 4 grams a day, omega-3 agents reduce triglycerides by 30% or more in people with very high levels. In the milder range, EPA-only and EPA-plus-DHA work about equally and neither raises LDL cholesterol. [2]

Note the dose. The advisory is explicitly about pharmacological amounts — above 3 grams a day of combined EPA and DHA. A standard supermarket fish oil capsule contains a fraction of that, and the label figure is usually total fish oil rather than actual EPA and DHA, which makes the gap wider than it looks.

There is also a trial showing hard outcomes at that dose. REDUCE-IT randomised 8,179 patients to 4 grams a day of a purified prescription EPA drug or placebo, and cut major cardiovascular events from 22.0% to 17.2% — a 25% relative reduction. [4]

Every word of the entry criteria matters, though. Those patients had established cardiovascular disease or diabetes with risk factors, were already taking a statin, and were selected for elevated triglycerides. It is a prescription drug trial in high-risk patients. It is not evidence for a gram of fish oil in a healthy forty-year-old, and it is regularly cited as though it were.

The side effect nobody mentions

This is the part of the fish oil story that has genuinely changed, and the marketing has not caught up.

In 2021, researchers pooled seven cardiovascular outcome trials covering 81,210 patients and looked specifically at atrial fibrillation — an irregular heart rhythm that raises stroke risk and often needs lifelong treatment. [5]

Omega-3 supplementation was associated with a 25% higher risk of atrial fibrillation. Hazard ratio 1.25, confidence interval 1.07 to 1.46.

And it was dose-dependent, which is the detail that makes it credible rather than a fluke. Above one gram a day: hazard ratio 1.49. At one gram a day or below: 1.12 — smaller, but with a confidence interval of 1.03 to 1.22, which still does not include “no effect”. The test for whether the two doses differed came out at p < 0.001, and a meta-regression found the risk climbing with every extra gram. [5]

We should report the tension here rather than tidy it away. Cochrane’s review found no effect on “arrhythmia” as a category — risk ratio 0.99, though at low certainty. [1] The 2021 analysis asked a narrower question, in a different set of trials, about atrial fibrillation specifically. Both are on the record. The narrower, more recent, dose-responsive one is the one we would want a doctor to know about.

The verdict

Fish oil supplements do not protect your heart, and that finding carries Cochrane’s highest certainty grade on both dying and cardiovascular events. The largest trial in healthy adults missed its primary endpoint. Small signals on coronary events survive at low certainty and a number needed to treat of 167.

Against that, a 25% higher risk of atrial fibrillation that rises with the dose.

The real benefit is narrow and it is genuine: at four grams a day, omega-3 lowers triglycerides substantially, and the American Heart Association recommends it for exactly that. If you have high triglycerides, that is a conversation with your doctor about a prescription — not a reason to buy a bigger tub.

If you do not, the honest summary is that you are taking a supplement with a high-certainty null on the outcome you care about and a dose-dependent signal on one you have probably never considered.

A note on what is coming: “fish oil versus krill oil” is one of the least contested questions in this whole area and one of the most searched. It deserves its own page, built on the bioavailability trials read properly rather than a paragraph tacked on here.

Related: do testosterone boosters work · ashwagandha benefits · berberine benefits · how to increase testosterone naturally

Sources
[1] Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2020;3(3):CD003177. doi:10.1002/14651858.cd003177.pub5
[2] Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation 2019;140(12):e673–e691. doi:10.1161/cir.0000000000000709
[3] Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine 2019;380(1):23–32. doi:10.1056/nejmoa1811403
[4] Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine 2019;380(1):11–22. doi:10.1056/nejmoa1812792
[5] Gencer B, Djoussé L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of long-term marine ω-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation 2021;144(25):1981–1990. doi:10.1161/circulationaha.121.055654